Compounding Chemotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Online Pharmacies is the fastest growing sector, North America is the largest market

The Global Compounding Chemotherapy Market is set to expand from USD 5.31 Billion in 2025 to USD 7.21 Billion by 2031, demonstrating a 5.23% CAGR. This market focuses on creating personalized antineoplastic medications in sterile environments, precisely tailored to individual cancer patients' unique dosing and formulation needs based on their physiological parameters, moving beyond standardized fixed-dose regimens. Growth is primarily driven by the increasing global cancer incidence and a rising clinical preference for precision medicine, which demands customized therapeutic protocols for optimal efficacy and toxicity management. Furthermore, the growing geriatric population's need for flexible dosage adjustments significantly sustains market demand.

Market Drivers

The expanding global incidence and prevalence of cancer serve as a fundamental catalyst for the growth of the compounding chemotherapy market. As the demographic burden of oncological diseases intensifies, there's a corresponding surge in the clinical demand for antineoplastic treatments that commercial mass production cannot always meet. Compounding pharmacies play a critical role in providing tailored solutions, especially for patients requiring precise dosage adjustments based on body surface area or specialized formulations.

According to the World Health Organization in February 2025, cancer remains a leading global cause of death, accounting for nearly 10 million fatalities, underscoring the vast patient volume requiring flexible and accessible chemotherapy options. Concurrently, persistent shortages of commercially available chemotherapy drugs significantly increase reliance on outsourcing and specialized compounders.

When conventional pharmaceutical supply chains encounter disruptions, hospitals turn to 503B compounding facilities for essential medications, such as cisplatin and carboplatin, to ensure continuous patient care. Data from Penn Medicine in December 2024 revealed that prescription rates for specific chemotherapy agents dropped by 15.1% during peak supply disruptions, highlighting the volatility of commercial access and driving substantial growth for compounding entities capable of mitigating these shortfalls. Fagron's March 2025 Annual Report noted a 17% increase in REBITDA, directly attributing this growth to robust demand for their compounding services, bolstered by ongoing drug shortages.

Market Challenges

Supply chain instability, particularly concerning raw materials and sterile injectables, represents a significant hurdle for the expansion of the compounding chemotherapy sector. Compounding facilities heavily depend on a consistent flow of specific antineoplastic agents to prepare personalized regimens. When global manufacturing consolidates or quality control issues interrupt production at major active pharmaceutical ingredient (API) facilities, compounding pharmacists face immediate inventory deficits.

This inability to procure base ingredients leads to operational slowdowns, hindering facilities from delivering the precise dosage adjustments that constitute their primary value proposition, thereby undermining the core advantage of the compounding model. The persistence of these shortages directly limits market throughput and revenue potential; for instance, the European Association of Hospital Pharmacists reported in late 2025 that nearly 64% of surveyed hospital pharmacists experienced patient therapy delays due to medicine shortages, with oncology drugs being among the most frequently affected. Such unpredictability forces healthcare providers to ration care or revert to standard fixed-dose alternatives to maintain treatment continuity. Consequently, the market's growth is constrained as the inability to ensure a reliable and continuous supply compromises the trust and consistency vital for time-sensitive cancer treatments.

Market Trends

The widespread adoption of robotic compounding automation is fundamentally transforming the sector by enhancing the precision of sterile preparations and significantly reducing healthcare worker exposure to hazardous antineoplastic agents. Hospitals and specialized pharmacies are increasingly integrating automated workflows to minimize human error in complex volumetric calculations and to safely contain cytotoxicity risks within controlled environments.

This technological shift is evidenced by the growing penetration of advanced verification systems, with the American Society of Health-System Pharmacists reporting in May 2024 that technologies assisting sterile product preparation are utilized in 62.8% of hospitals, highlighting the critical transition toward automated safety protocols. Simultaneously, the market is experiencing substantial growth in home-based chemotherapy infusion services, driven by a shift towards patient-centric care models that prioritize convenience and aim to reduce hospitalization costs. This trend alleviates the logistical burden on busy oncology centers and allows immunocompromised patients to receive essential treatments in lower-risk home environments. The escalating demand for these remote care capabilities is reflected in the financial performance of major providers; for example, Option Care Health reported a 16.2% net revenue increase for the full year 2024, attributing this surge to the expanded utilization of home and alternate site infusion therapies.

Key Market Players

• Pfizer Inc.
• Baxter International Inc.
• Grifols SA
• Comecer S.P.A.
• Arxium Inc.
• Dedalus Group
• B. Braun Melsungen AG
• Omnicell Technologies Inc.
• The Metrix Company
• Sterline S.R.L

Report Scope

In this report, the Global Compounding Chemotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounding Chemotherapy Market, by Drug Type:

• Cytotoxic Drugs
• Hormonal Agents
• Immunomodulatory Agents
• Targeted Therapies
• Supportive Care Drugs

Compounding Chemotherapy Market, by Route of Administration:

• Intravenous
• Oral
• Subcutaneous
• Intramuscular
• Intrathecal

Compounding Chemotherapy Market, by Cancer Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Leukemia
• Lymphoma

Compounding Chemotherapy Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Compounding Chemotherapy Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Compounding Chemotherapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.